An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

NCT00000721 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: CD4 Antigens

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]